Búsqueda de: drug-eluting stents

Si no está conforme con los resultados, inténtelo de nuevamente.

Treatment of Recurrent In-Stent Restenosis with Drug-Eluting Stents: 10-Year Outcomes

In-stent restenosis (ISR) remains the main limitation in the percutaneous treatment of coronary artery disease, with a...
Ir

Long-Term Results from the BEST Study: Drug-Eluting Stents vs. Bypass Surgery in Diabetic Patients with Multiple Vessel Disease

The impact of diabetes on the development of cardiovascular disease is widely known, with a strong association...
Ir

Drug-Eluting Stents vs. Balloons While Paclitaxel Is in the Eye of the Storm

Even after the US Food and Drug Administration (FDA) issued an alert on paclitaxel devices in patients...
Ir

TCT 2018 | IMPERIAL: First Study Comparing Drug-Eluting Stents in Patients with Femoropopliteal Disease

The IMPERIAL trial compared the safety and efficacy of a nitinol self-expanding polymer-free placlitaxel-eluting stent (Zilver PTX,...
Ir

Bioresorbable scaffolds with drug-eluting stents: do they entail a higher thrombosis risk?

Courtesy of Dr. Leiva. Bioresorbable scaffolds with drug-eluting stents (bioresorbable vascular scaffolds, BVS) have been added to the...
Ir

Very Late Thrombosis: Bioresorbable Scaffolds vs. Everolimus-Eluting Metallic Drug-Eluting Stents

This study sought to compare the 2-year outcomes between bioresorbable vascular scaffolds (BVS) and everolimus-eluting metallic drug-eluting...
Ir

IVUS vs. Angiography in New-Generation Drug-Eluting Stents Preimplantation

Courtesy of Dr. Guillermo Migliaro. The latest 2011 American College of Cardiology (ACC) guideline states that “coronary intravascular ultrasonography (IVUS)...
Ir

I-LOVE-IT2: Drug-eluting stents with a permanent polymer versus biodegradable in the same cobalt chromium platform

There is no strong evidence in the literature that the polymer type isolated (permanent or degradable) influences...
Ir